Resverlogix Corp. (RVXCF)
USD 0.03
(-2.79%)
USD 0.03
(-2.79%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -3.61 Million USD | 85.43% |
| 2021 | -24.77 Million USD | 0.0% |
| 2019 | 118.02 Million USD | 172.5% |
| 2018 | -162.79 Million USD | -179.19% |
| 2017 | -58.31 Million USD | -26.18% |
| 2016 | -46.21 Million USD | -134.39% |
| 2015 | -19.71 Million USD | -7.6% |
| 2014 | -18.32 Million USD | 66.75% |
| 2013 | -55.1 Million USD | -227.1% |
| 2012 | 43.35 Million USD | 130.83% |
| 2011 | 18.78 Million USD | 802.11% |
| 2010 | 2.08 Million USD | 107.58% |
| 2009 | -27.46 Million USD | -51.73% |
| 2008 | -18.1 Million USD | 35.64% |
| 2007 | -28.12 Million USD | -69.97% |
| 2006 | -16.54 Million USD | -159.22% |
| 2005 | -6.38 Million USD | -124.99% |
| 2004 | -2.83 Million USD | -101.11% |
| 2003 | -1.41 Million USD | -175.11% |
| 2002 | -512.82 Thousand USD | -173.81% |
| 2001 | -187.29 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | -4.44 Million USD | -10.81% |
| 2023 Q2 | -4.01 Million USD | 0.0% |
| 2022 Q4 | 801 Thousand USD | 147.79% |
| 2022 Q2 | -403 Thousand USD | 82.72% |
| 2022 FY | -3.61 Million USD | 85.43% |
| 2022 Q3 | -1.67 Million USD | -315.88% |
| 2022 Q1 | -2.33 Million USD | 86.2% |
| 2021 Q4 | -16.89 Million USD | -219.64% |
| 2021 Q1 | 20 Thousand USD | 0.0% |
| 2021 FY | -24.77 Million USD | 0.0% |
| 2021 Q2 | -2.6 Million USD | -13145.0% |
| 2021 Q3 | -5.28 Million USD | -102.61% |
| 2020 Q3 | -3.42 Million USD | 44.91% |
| 2020 Q1 | 8.72 Million USD | 86.39% |
| 2020 Q2 | -6.2 Million USD | -171.18% |
| 2019 FY | 118.02 Million USD | 172.5% |
| 2019 Q4 | 4.67 Million USD | -95.35% |
| 2019 Q3 | 100.66 Million USD | 2442.71% |
| 2019 Q2 | 3.95 Million USD | 106.52% |
| 2019 Q1 | -60.69 Million USD | -352.77% |
| 2018 Q3 | -39.2 Million USD | 20.79% |
| 2018 Q1 | -8.2 Million USD | 65.62% |
| 2018 Q2 | -49.49 Million USD | -503.03% |
| 2018 Q4 | -13.4 Million USD | 65.8% |
| 2018 FY | -162.79 Million USD | -179.19% |
| 2017 Q3 | -10.87 Million USD | 29.18% |
| 2017 FY | -58.31 Million USD | -26.18% |
| 2017 Q4 | -23.87 Million USD | -119.51% |
| 2017 Q1 | -11.57 Million USD | 10.97% |
| 2017 Q2 | -15.35 Million USD | -32.72% |
| 2016 FY | -46.21 Million USD | -134.39% |
| 2016 Q1 | -9.67 Million USD | -9.06% |
| 2016 Q3 | -15.16 Million USD | -134.06% |
| 2016 Q4 | -12.99 Million USD | 14.31% |
| 2016 Q2 | -6.47 Million USD | 33.06% |
| 2015 Q4 | -8.87 Million USD | -133.25% |
| 2015 Q3 | -3.8 Million USD | -243.97% |
| 2015 Q1 | 16.69 Million USD | 1107.66% |
| 2015 Q2 | 2.64 Million USD | -84.17% |
| 2015 FY | -19.71 Million USD | -7.6% |
| 2014 FY | -18.32 Million USD | 66.75% |
| 2014 Q4 | -1.65 Million USD | 50.37% |
| 2014 Q3 | -3.33 Million USD | -150.42% |
| 2014 Q2 | 6.62 Million USD | 1889.73% |
| 2014 Q1 | -370 Thousand USD | -102.42% |
| 2013 Q4 | 15.28 Million USD | 893.82% |
| 2013 Q1 | 12.27 Million USD | -4.22% |
| 2013 Q2 | -41.37 Million USD | -436.99% |
| 2013 Q3 | -1.92 Million USD | 95.35% |
| 2013 FY | -55.1 Million USD | -227.1% |
| 2012 Q1 | -6.84 Million USD | -202.87% |
| 2012 Q2 | 7.95 Million USD | 216.24% |
| 2012 FY | 43.35 Million USD | 130.83% |
| 2012 Q3 | 10.3 Million USD | 29.53% |
| 2012 Q4 | 12.82 Million USD | 24.43% |
| 2011 Q4 | 6.65 Million USD | 252.01% |
| 2011 Q1 | -6.76 Million USD | -139.86% |
| 2011 Q2 | -912 Thousand USD | 86.51% |
| 2011 Q3 | -4.37 Million USD | -379.82% |
| 2011 FY | 18.78 Million USD | 802.11% |
| 2010 Q2 | 13.4 Million USD | 236.26% |
| 2010 Q4 | 16.96 Million USD | 171.77% |
| 2010 FY | 2.08 Million USD | 107.58% |
| 2010 Q1 | -9.84 Million USD | -20.68% |
| 2010 Q3 | -23.64 Million USD | -276.31% |
| 2009 Q4 | -8.15 Million USD | -88.77% |
| 2009 FY | -27.46 Million USD | -51.73% |
| 2009 Q3 | -4.31 Million USD | 14.64% |
| 2009 Q2 | -5.06 Million USD | -21.72% |
| 2009 Q1 | -4.15 Million USD | 21.0% |
| 2008 FY | -18.1 Million USD | 35.64% |
| 2008 Q2 | -5.03 Million USD | 28.69% |
| 2008 Q3 | -4.62 Million USD | 8.08% |
| 2008 Q4 | -5.26 Million USD | -13.74% |
| 2008 Q1 | -7.05 Million USD | -13.24% |
| 2007 FY | -28.12 Million USD | -69.97% |
| 2007 Q3 | -8.31 Million USD | -26.78% |
| 2007 Q2 | -6.56 Million USD | 20.91% |
| 2007 Q1 | -8.29 Million USD | -113.88% |
| 2007 Q4 | -6.23 Million USD | 25.05% |
| 2006 Q1 | -2.05 Million USD | -58.25% |
| 2006 FY | -16.54 Million USD | -159.22% |
| 2006 Q2 | -1.76 Million USD | 14.1% |
| 2006 Q3 | -2.82 Million USD | -59.83% |
| 2006 Q4 | -3.87 Million USD | -37.48% |
| 2005 Q3 | -1.77 Million USD | -57.83% |
| 2005 FY | -6.38 Million USD | -124.99% |
| 2005 Q2 | -1.12 Million USD | -22.43% |
| 2005 Q1 | -916.5 Thousand USD | 0.17% |
| 2005 Q4 | -1.29 Million USD | 26.69% |
| 2004 Q1 | -729.77 Thousand USD | -213.3% |
| 2004 FY | -2.83 Million USD | -101.11% |
| 2004 Q2 | -440.22 Thousand USD | 39.68% |
| 2004 Q3 | -539.89 Thousand USD | -22.64% |
| 2004 Q4 | -918.04 Thousand USD | -70.04% |
| 2003 Q1 | -248.24 Thousand USD | -161.06% |
| 2003 Q3 | -146.28 Thousand USD | 48.73% |
| 2003 Q4 | -232.92 Thousand USD | -59.23% |
| 2003 Q2 | -285.33 Thousand USD | -14.94% |
| 2003 FY | -1.41 Million USD | -175.11% |
| 2002 Q3 | -12.95 Thousand USD | 49.44% |
| 2002 Q4 | -95.09 Thousand USD | -634.03% |
| 2002 Q2 | -25.62 Thousand USD | -436.37% |
| 2002 Q1 | -4777.27 USD | 0.0% |
| 2002 FY | -512.82 Thousand USD | -173.81% |
| 2001 FY | -187.29 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -170.325% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 48.302% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 106.814% |
| Nascent Biotech, Inc. | -2.08 Million USD | -72.919% |
| Rebus Holdings, Inc. | -1.02 Million USD | -253.922% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 105.543% |
| Qrons Inc. | -789.34 Thousand USD | -357.34% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -470.835% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 94.233% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -768.877% |
| Skye Bioscience, Inc. | -37.64 Million USD | 90.41% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 95.184% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 45.104% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1220.4% |
| SQZ Biotechnologies Company | -79.46 Million USD | 95.457% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -24.81% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -98.294% |
| Mesoblast Limited | -87.95 Million USD | 95.896% |
| Marizyme, Inc. | -65.34 Million USD | 94.476% |
| Genus plc | 7.9 Million USD | 145.696% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 66.856% |
| Pharming Group N.V. | -10.54 Million USD | 65.776% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -66.374% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 2.702% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 59.181% |
| ContraFect Corporation | -65.15 Million USD | 94.459% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 26.116% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -108.978% |
| IMV Inc. | -36.48 Million USD | 90.106% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 55.209% |
| MultiCell Technologies, Inc. | -380.07 USD | -949725.032% |
| ONE Bio Corp. | 8.67 Million USD | 141.606% |
| Accustem Sciences Inc. | -3.74 Million USD | 3.641% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 93.016% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -184.895% |
| Q BioMed Inc. | -2.05 Million USD | -75.918% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 3.295% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -51.625% |
| Biomind Labs Inc. | -1.21 Million USD | -197.286% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 93.956% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -16.385% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 54.322% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -85.2% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -24005.235% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 77.255% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 37.943% |
| GB Sciences, Inc. | -1.36 Million USD | -165.114% |
| Alpha Cognition Inc. | -13.77 Million USD | 73.788% |
| HST Global, Inc. | -146.21 Thousand USD | -2369.051% |
| CSL Limited | 2.64 Billion USD | 100.137% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -105.725% |
| Halberd Corporation | -79.67 Thousand USD | -4430.85% |
| Enzolytics Inc. | -2.17 Million USD | -65.837% |
| Agentix Corp. | -1.37 Million USD | -162.696% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -13.829% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.776% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3783.673% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 152.133% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 9.137% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -19.294% |
| AVAX Technologies, Inc. | -6.41 Million USD | 43.714% |
| Zenith Capital Corp. | -10.59 Million USD | 65.931% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.219% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -15432.226% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 12.927% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -5872.805% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -80.04% |
| Kadimastem Ltd | -3.3 Million USD | -9.149% |
| Helix BioMedix, Inc. | -1.05 Million USD | -241.838% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 5.473% |
| BioStem Technologies, Inc. | -8.48 Million USD | 57.444% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -717.91% |
| LadRx Corporation | 400.44 Thousand USD | 1001.502% |
| Cell Source, Inc. | -5.32 Million USD | 32.158% |
| Regen BioPharma, Inc. | 1.02 Million USD | 452.709% |
| Regen BioPharma, Inc. | 1.02 Million USD | 452.709% |
| NovAccess Global Inc. | -4.76 Million USD | 24.306% |
| Affymax, Inc. | -14.42 Million USD | 74.972% |
| Itoco Inc. | -1.86 Million USD | -93.152% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 18.74% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -116.297% |
| Mobile Lads Corp. | -2.26 Million USD | -59.502% |
| CytoDyn Inc. | -49.84 Million USD | 92.757% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -4467.712% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1482.452% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -283.419% |
| SYBLEU INC | -180.3 Thousand USD | -1902.174% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -123.843% |
| International Stem Cell Corporation | -131 Thousand USD | -2655.725% |
| Bioxytran, Inc. | -4.28 Million USD | 15.654% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -6551.68% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -42.674% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 92.49% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -70.766% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -362.295% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -13.952% |
| Neutra Corp. | -233.46 Thousand USD | -1446.27% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 82.209% |
| PureTech Health plc | -65.69 Million USD | 94.505% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 83.025% |
| IXICO plc | -1.17 Million USD | -206.452% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 63.635% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 93.681% |
| CSL Limited | 2.64 Billion USD | 100.137% |
| Cellectis S.A. | -103.17 Million USD | 96.501% |